![](/wp-content/uploads/2018/10/wTGxMfc0TvO5zttwrjI8.png)
$599
Zealand Announces Additional Topline Dasiglucagon Results
Zealand has announced positive topline results from its Ph3 dasiglucagon immunogenicity study. Recall, in March 2018, the company reported results stating the trial met primary and secondary endpoints.